37 results about "Infantile haemangioma" patented technology

The invention discloses application of external timolol preparations in treating infantile hemangioma and a preparation method thereof, belongs to the field of pharmacy and aims to providing various timolol preparations supportive of external use and used for treating infantile hemangioma. Various external preparations like gels, plastics, paste and pigmentum can be prepared by adding proper auxiliary materials like gel substrate, percutaneous penetration enhancer, preservative, humectant, emulsifier, film forming material and oily substrate. The external timolol preparations have the advantages of high safety, accurate curative effect, high tolerance and quickness in taking effect.

The invention relates to a timolol long-acting transdermal preparation, comprising the following preparation processes: firstly preparing timolol into a timolol nano-drug or timolol micro-powder, and then preparing the timolol nano-drug or timolol micro-powder into a timolol hydrogel transdermal preparation, an ointment transdermal preparation or a micro-needle transdermal preparation. The invention also relates to an application of the drug in hemangioma treatment. When used for treating infantile hemangioma, the medicine disclosed by the invention is capable of improving the medicine absorption efficiency of the pathological cells, and therefore the treatment effect is improved, the dosage is lowered, and no adverse reactions are generated in the treatment process.

The invention relates to a preparation method of an ointment for treating infantile hemangioma. The preparation method comprises the following steps: adding timolol hydrogenmaleate, propranolole hydrochloride, tacrolimus, pingyangmycin, vitamin C, vitamin E and vitamin B12 to water according to certain mass ratio, heating to 30-85 DEG C of the temperature, adding a thickener, imiquimod and a wetting agent according to certain mass ratio after stirring and dissolving, and uniformly stirring, and preparing the ointment for treating the infantile hemangioma after cooling. The ointment for treating the infantile hemangioma is an external used medicine, particularly suitable for the infants inconvenient for taking medicines and injection.

The present invention relates to methods and compositions designed for the treatment, management, prevention and / or amelioration of non-neoplastic hyperproliferative epithelial and / or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and / or aberrant angiogenesis. Non-limiting examples of such disorders include cirrhosis, fibrosis (e.g., fibrosis of the liver, kidney, lungs, heart, retina and other viscera), asthma, ischemia, atherosclerosis, diabetic retinopathy, retinopathy of prematurity, vascular restenosis, macular degeneration, rheumatoid arthritis, osteoarthritis, infantile hemangioma, verruca vulgaris, Kaposi's sarcoma, neurofibromatosis, recessive dystrophic epidermolysis bullosa, ankylosing spondylitis, systemic lupus, Reiter's syndrome, Sjogren's syndrome, endometriosis, preeclampsia, atherosclerosis, coronary artery disease, psoriatic arthropathy and psoriasis. The methods of the invention comprise the administration of an effective amount of one or more agents that are modulators of EphA2 and / or its endogenous ligand, EphrinA1. The invention also provides pharmaceutical compositions comprising one or more EphA2 / EphrinA1 Modulators of the invention either alone or in combination with one or more other agents useful for therapy for such non-neoplastic hyperproliferative epithelial and / or endothelial disorders. Diagnostic methods and methods for screening for EphA2 / EphrinA1 Modulators are also provided.

The invention discloses a propranolol hydrochloride cream used for treating infantile hemangioma, and a preparation method thereof. The cream comprises the components of, by weight, 0.8-1.2% of propranolol hydrochloride, 5.5-8% of octadecanol, 5.5-8% of glycerol monostearate, 5.5-8% of stearic acid, 7.5-10.5% of liquid paraffin, 7.5-10.5% of glycerol, 7.5-10.5% of propylene glycol, 1.5-2.5% of an emulsifier, 0.4-0.6% of a penetration enhancer, 0.08-0.12% of a preservative, and balance of water. The propranolol hydrochloride cream provided by the invention has good stability, and an effective duration of at least 24 months. The cream can directly act upon an infection site, such that local medicine concentration is high, and adverse reactions caused by oral administration or intravenous administration can be avoided. With the cream, medicine effect can be maximized, and medicine side effect can be reduced. The cream has a definite effect, and is suitable for industrialized large-scale productions. The cream is used for treating hemangioma and is especially suitable for treating infantile hemangioma.

The invention discloses propranolol hydrochloride submicron emulsion gel and a preparation method and application thereof. The propranolol hydrochloride submicron emulsion gel comprises propranolol hydrochloride and pharmaceutical acceptable medicinal excipients, wherein the medicinal excipients comprise oil, a surfactant, a cosurfactant, a penetration enhancer, a gel substrate, a pH conditioning agent and the balance water. The propranolol hydrochloride submicron emulsion gel can efficiently deliver the propranolol hydrochloride to skin tissue to enable drugs to be released slowly, skin targeted drug delivery treatment on superficial infantile hemangioma is achieved, and the problems that for an existing drug, the curative effect is low, the side effect is large, and the transdermal absorption ratio is low are effectively solved.

The invention relates to a pharmaceutical composition for external use. The pharmaceutical composition is characterized by simultaneously containing timolol and allantoin, wherein, timolol can be a free alkali form, and also can be an any pharmaceutically acceptable salt form. The composition preparation has good stability and permeability, and has obvious curative effect for infantile hemangioma.

The invention provides a composite phospholipid transfersome which promotes propranolol percutaneous absorption, and a preparation method thereof. According to the invention, two phospholipid materials with different phase-change temperatures, which are dipalmitoyl phosphatidyl choline and soybean lecithin, are adopted as a composite phospholipid material. Compared with a transfersome with a single phospholipid material in prior art, the propranolol composite phospholipid transfersome prepared with the phospholipid material provided by the invention has substantially improved encapsulation efficiency, reduced leakage, improved stability in rat plasma, and substantially improved bioavailability after percutaneous administration. The propranolol composite phospholipid transfersome provided by the invention is especially suitable to be used for treating infantile hemangioma. With the transfersome, propranolol percutaneous administration can be realized, and propranolol can directly act upon a hemangioma affected part. The treatment effect is improved, toxic and side effects are reduced, and children medication compliance can be improved. Also, the invention provides a preparation method of the propranolol composite phospholipid transfersome.

The invention belongs to the field of preparations and relates to a timolol maleate pharmaceutical composition and a preparation method thereof. The timolol maleate pharmaceutical composition contains timolol maleate, Carbopol, triethanolamine, propylene glycol, ethylparaben and water. The pharmaceutical composition has the advantages of good biocompatibility, easiness in coating, no greasiness and the like, and the use compliance of a patient is greatly improved; the timolol maleate pharmaceutical composition can directly act on a focus of infection, and the local drug concentration is increased, so that the drug effect is furthest exerted, and the untoward effect of the whole body caused due to oral medication or intravenous medication is avoided; and the pharmaceutical composition is suitable for industrial large-scale production, is used for treating hemangioma and is particularly suitable for treating superficial type infantile hemangioma.

The present technology relates the use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas, for example of infantile hemangiomas. The beta blocker may be a non-selective beta-blocker, for example propranolol. The present technology provides an alternative to the known compounds, e.g. corticosteroids, interferon or vincristine, generally used for the treatment of hemangiomas.

The present invention relates to methods and compositions designed for the treatment, management, prevention and / or amelioration of non-neoplastic hyperproliferative epithelial and / or endothelial cell disorders, including but not limited to disorders associated with increased deposition of extracellular matrix components (e.g., collagen, proteoglycans, tenascin and fibronectin) and / or aberrant angiogenesis. Non-limiting examples of such disorders include cirrhosis, fibrosis (e.g., fibrosis of the liver, kidney, lungs, heart, retina and other viscera), asthma, ischemia, atherosclerosis, diabetic retinopathy, retinopathy of prematurity, vascular restenosis, macular degeneration, rheumatoid arthritis, osteoarthritis, infantile hemangioma, verruca vulgaris, Kaposi's sarcoma, neurofibromatosis, recessive dystrophic epidermolysis bullosa, ankylosing spondylitis, systemic lupus, Reiter's syndrome, Sjogren's syndrome, endometriosis, preeclampsia, atherosclerosis, coronary artery disease, psoriatic arthropathy and psoriasis. The methods of the invention comprise the administration of an effective amount of one or more agents that are modulators of EphA2 and / or its endogenous ligand, EphrinA1. The invention also provides pharmaceutical compositions comprising one or more EphA2 / EphrinA1 Modulators of the invention either alone or in combination with one or more other agents useful for therapy for such non-neoplastic hyperproliferative epithelial and / or endothelial disorders. Diagnostic methods and methods for screening for EphA2 / EphrinA1 Modulators are also provided.

The invention relates to a propranolol hydrochloride oral administration emulsion for treating infantile hemangioma and a preparation method thereof. The oral administration emulsion is prepared from 0.25 to 40 parts by weight of propranolol hydrochloride, 70 to 300 parts by weight of oil phase, 22 to 200 parts by weight of emulsifiers, 15 to 101.5 parts by weight of co-emulsifiers and 352 to 1570 parts by weight of purified water. The propranolol hydrochloride oral administration emulsion provided by the invention solves the problem that no special oral administration preparation for treating infantile hemangioma exists in China at present. The propranolol hydrochloride oral administration emulsion provided by the invention overcomes the defect of a phenomenon of tablet and capsule taking difficulty due to infant pharyngeal narrowing. The propranolol hydrochloride is used as an effective ingredient to be uniformly dispersed in the emulsion; the administration dosage can be precisely mastered; the excessive treatment or insufficient treatment can be avoided.

The invention provides application of levo-propranolol in preparing a medicament for treating vasculopathy. During treatment of vasculopathy, particularly treatment of hemangioma, the treatment effectof the levo-propranolol is better than those of racemic propranolol and dextro-propranolol, and a good prospect is provided for the clinical treatment of hemangioma or infantile hemangioma.

The invention provides an oral membrane for treating infantile hemangioma and a preparation method thereof. The oral membrane comprises a beta-acceptor block and pharmaceutically-acceptable ingredients. Each piece of the oral membrane is accurate in medicine content, and the oral membrane can be administrated conveniently, accurately and quantitatively, is convenient for infantile patients to use,capable of ensuring treatment effect and completely suitable for industrial large-scale production.

The invention discloses a method for automatically extracting and quantifying the color of a lesion area of an infantile hemangioma. The method comprises the steps of extracting a lesion part in an image of the infantile hemangioma, marking the lesion part as the lesion area and marking the remaining part as a skin area; converting color space of the lesion area and the skin area from red green blue (RGB) to international commission on illumination (CIE) Lab; extracting a mean value of chromatic values of three channels of the skin area to obtain a mean vector of the chromatic value of the skin area; extracting the mean value of chromatic values of three color channels of the lesion area to obtain the mean vector of the chromatic value of the lesion area; calculating distance by utilizingthe mean vector of the chromatic value of the skin area and the mean vector of the chromatic value of the lesion region, wherein the distance comprises Euclidean distance, Manhattan distance, Chebyshev distance, included angle cosine distance and related distance; and inputting the distance into an SVM (Support Vector Machine) classification model and outputting a classification result to realizeautomatic quantification of the color of the lesion area of the infantile hemangioma. Through the method disclosed by the invention, the automatic extraction and quantification of the color of the lesion area of the infantile hemangioma are realized.

The invention provides gel for infantile hemangioma and a preparation method of the gel, and belongs to the technical field of pharmaceutical preparations. The gel for infantile hemangioma consists ofpropranolol, timolol maleate, NVP-Gelbert alcohol maleate monoester copolymer, vaseline, liquid paraffin, glycerin monostearate, lauryl sodium sulfate, glycerinum, ethylparaben and water. The gel forhemangioma has the advantages of being easy to prepare, convenient to use, capable of taking effect fast, long in acting time, remarkable in treatment effect and the like, the acting time of the drugis prolonged through the NVP-Guerbet alcohol maleate monoester copolymer, the biocompatibility of the drug is improved, and the advantage of controlled release is achieved. The gel for hemangioma issuitable for industrial large-scale production and used for treating infantile hemangioma.

The invention provides a propranolol hydrochloride gel preparation for external use and a preparation method and application thereof. The propranolol hydrochloride gel preparation for the external use contains at least 3% by weight of propranolol hydrochloride. The propranolol hydrochloride gel preparation for the external use has good stability and skin permeability and has a significant curative effect on treatment and prevention of infantile hemangioma located in different subcutaneous depths.

The invention provides a propranolol hydrochloride smearing preparation and a preparation method and application thereof. The propranolol hydrochloride smearing preparation is prepared from, by weight, 1%-8% of propranolol hydrochloride, 2.5%-15% of substrate, 2%-10% of skin penetration enhancer, 3%-16% of moisturizing agent, 0.02%-0.2% of bacteriostatic agent and the balance water. The propranolol hydrochloride smearing preparation is small in skin irritation and capable of directly acting on infantile hemangioma ulcer parts to rapidly facilitate ulcer healing and treating hemangioma simultaneously.

The invention relates to compound propranolol hydrochloride oral liquid for treating infantile hemangiomas. The compound propranolol hydrochloride oral liquid comprises the following raw materials byweight of 100-300g of endothelium corneum gigeriae galli, 200-400g of haws, 100-300g of duchesnea indica, 200-300g of bigleaf beautyberry leaves, 200-400g of radix salviae miltiorrhizae, 100-300g of lotus leaves and 30-50g of propranolol hydrochloride. Compared with the prior art, the compound propranolol hydrochloride oral liquid disclosed by the invention has the advantages that the quality andthe effects are notably improved, and the compound propranolol hydrochloride oral liquid is high in cure rate, low in adverse reaction rate, good in mouth feel, easy in infantile administration, smallin dosage and good in biological availability and have enormous social and economic benefits.

The invention provides a timolol maleate liposome gel and a preparation method thereof. The gel is prepared from timolol maleate, a penetration enhancer, a humectant, a preservative, a liposome forming agent, a gel matrix, a pH regulator and medical purified water. The prepared timolol maleate liposome gel is uniform and delicate, suitable in viscosity and easy to spread, the drug release time is prolonged through the liposome technology, the concentration of the drug at the diseased region is kept, the gel is used for treating infantile hemangioma, drug administration is convenient, meanwhile, the first-pass effect of the liver is avoided, and meanwhile the gel is convenient to use, high in safety, simple in production process and good in application prospect.

The invention provides a composite phospholipid transfersome which promotes propranolol percutaneous absorption, and a preparation method thereof. According to the invention, two phospholipid materials with different phase-change temperatures, which are dipalmitoyl phosphatidyl choline and soybean lecithin, are adopted as a composite phospholipid material. Compared with a transfersome with a single phospholipid material in prior art, the propranolol composite phospholipid transfersome prepared with the phospholipid material provided by the invention has substantially improved encapsulation efficiency, reduced leakage, improved stability in rat plasma, and substantially improved bioavailability after percutaneous administration. The propranolol composite phospholipid transfersome provided by the invention is especially suitable to be used for treating infantile hemangioma. With the transfersome, propranolol percutaneous administration can be realized, and propranolol can directly act upon a hemangioma affected part. The treatment effect is improved, toxic and side effects are reduced, and children medication compliance can be improved. Also, the invention provides a preparation method of the propranolol composite phospholipid transfersome.

Melts or ionic liquids containing amorphous propranolol, topical formulations and patches for transdermal drug delivery, and methods of making and using thereof are described herein. The melts or ionic liquids may be in a topical drug delivery formulation or patch to be applied to the skin. The drug delivery formulation or patch contains a sufficient amount of the amorphous propranolol to deliver a therapeutically effective amount of the amorphous propranolol to the patient in need of treatment, such as for the treatment or amelioration of infantile hemangioma. The formulations have a low viscosity and reduced skin irritation compared to the crystalline propranolol free base (PFB). The melts or ionic liquids can be formed by a salt metathesis reaction.

The invention provides a hemangioma gel containing an amphiphilic polymer and a preparation method thereof, belonging to the technical field of pharmaceutical preparations. The invention provides a hemangioma gel containing an amphiphilic polymer, which is composed of propranolol or timolol maleate, NVP-maleic acid monodocosanol monoester copolymer, Tween-80 , sodium lauryl sulfate, propylene glycol, silicone oil, vaseline, chlorobutanol and purified water; the hemangioma gel has the characteristics of simple preparation, convenient use, quick onset, long acting time, and remarkable therapeutic effect. NVP ‑Docosanol monoester maleate copolymer increases the action time of the drug, improves the biocompatibility of the drug, has the advantages of slow and controlled release, and reduces the use of transdermal accelerators; the hemangioma coagulation agent of the present invention The glue is suitable for industrialized large-scale production and is used for treating infantile hemangioma.

The invention belongs to the technical field of medicines, and discloses atenolol gel used for treating infantile hemangioma, a preparation method and applications. The atenolol gel used for treating infantile hemangioma includes 5% of atenolol gel. The atenolol gel consists of atenolol and solid gel. The content of the atenolol in each gram of the atenolol gel is 50 mg. The preparation method of the atenolol gel includes obtaining the atenolol gel by mixing 50 mg of the atenolol and the solid gel. The atenolol gel can be used for treating infantile hemangioma, and is good in treatment effect, less in adverse reaction, wide in indication; and the atenolol gel is longer in half life, less in drug use frequency, better in medical compliance, and lower in cost. By using the atenolol gel to treat the hemangioma in an external use manner, risks of adverse reactions, such as gastrointestinal discomfort (diarrhea) and mood changes, caused by oral drugs can be avoided.

The invention discloses itraconazole drops and a preparation method thereof. The itraconazole drops are prepared from components in parts by weight as follows: 1-3 parts of itraconazole, 80-120 partsof vitamin E acetate, 5-15 parts of vitamin A1 and 10-30 parts of PEG400. According to the itraconazole drops, itraconazole is in a dissolved state, has good stability, can be directly absorbed instead of being dissolved in gastrointestinal tracts and can improve the biocompatibility. Besides, the preparation technology is simple, auxiliary materials are high in safety, and the itraconazole dropscan be taken with milk or added to milk to be taken and are particularly applicable to treatment of infantile hemangioma.

The invention relates to the technical field of medicine and provides propranolole hydrochloride gel and a preparation method thereof. The propranolole hydrochloride gel is mainly prepared from the ingredients of bulk drug propranolole hydrochloride, penetration enhancer, humectant, preservative, gel substrate and water. A propranolole hydrochloride gel preparation prepared by the invention has the characteristics of being even, fine, appropriate in viscosity, easy to smear and free of irritation to skin; when being applied to treating subcutaneous-layer infantile hemangioma, the propranolole hydrochloride gel preparation is convenient to dose and avoids a first-pass effect of the liver; furthermore, the gel preparation can form a drug storage library on the skin, so that a slow-release function is achieved; meanwhile, the gel preparation is better in child patient adaptability and has good application prospect.

The invention discloses an itraconazole drop and a preparation method thereof, comprising the following components: 1-3 parts by weight of itraconazole, 80-120 parts by weight of vitamin E acetate, 5-15 parts by weight of vitamin A1, 10-30 parts by weight of PEG400. In the itraconazole drops disclosed in the invention, the itraconazole is in a dissolved state and has good stability, and can be directly absorbed without a dissolution step in the gastrointestinal tract, which is beneficial to improve bioavailability. In addition, the preparation process is simple, the auxiliary materials are high in safety, can be administered with milk or added to milk for administration, and is especially suitable for the treatment of infantile hemangioma.

The present invention describes stem cells and progenitor cells derived from hemangiomas, including testing of angiogenic inhibitors using these cells. The invention as described is useful in providing a process to culture and propagate hemangioma stem cells and generate xenograft models to develop treatments for infantile hemangiomas and other types of vascular lesions.

The invention relates to a compound propranolol hydrochloride oral liquid for treating hemangioma in children, which comprises the following raw materials by weight: 100-300g of Gallus gallis, 200-400g of Hawthorn, 100-300g of Snakeberry, and 200-300g of Purple Pearl Leaf , Salvia miltiorrhiza 200-400g, lotus leaf 100-300g and propranolol hydrochloride 30-50g; Compared with the prior art, the present invention has significantly improved quality and effect, high cure rate, low adverse reaction rate, and good mouthfeel , easy to administer to children, small dosage, good bioavailability, and huge social and economic benefits.